About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 4662 record(s)
Req # A-2021-001275
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-115423-145.Organization: Health Canada
September 2022
Req # A-2021-001528
Adverse Drug Reactions (ADRs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_03608726, E2B_03944620, E2B_04048425, E2B_04048807, E2B_03782781, E2B_03611346, 951380, E2B_03755276, E2B_03888456, E2B_03742843, E2B_03739983, E2B_03739980,…Organization: Health Canada
September 2022
Req # A-2021-001570
Adverse Drug Reactions (ADRs) for TRIAMCINOLONE ACETONIDE. Report numbers: E2B_04554793, E2B_04511783, E2B_04584019, E2B_04574685, E2B_04583624.Organization: Health Canada
September 2022
Req # A-2021-001777
Adverse Drug Reactions (ADRs) for ALEMTUZUMAB. Report numbers: E2B_04159280, E2B_04611064, E2B_04520249, E2B_04314028, E2B_04577064, 000954344, E2B_04283693, E2B_04595132.Organization: Health Canada
September 2022
Req # A-2021-001851
Adverse Drug Reactions (ADRs) for . Report numbers: E2B_02556924, E2B_02558657, E2B_02558683, E2B_02601677, 000722528, E2B_02323103, E2B_02341451, E2B_02397634, E2B_02397638, E2B_02531761.Organization: Health Canada
September 2022
Req # A-2021-001880
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-075691-519.Organization: Health Canada
September 2022
Req # A-2021-001999
Adverse Drug Reactions (ADRs) for Temodal. Report numbers: 000716723, 000719302, E2B_01685263, E2B_01730824, E2B_01995108, E2B_02050959, E2B_02052614, E2B_02067205, E2B_02067471, E2B_02067479.Organization: Health Canada
September 2022
Req # A-2021-002040
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-100122-522, Meeting with Mayor of Edmonton.Organization: Health Canada
September 2022
Req # A-2021-002072
Adverse Drug Reactions (ADRs) for FUROSEMIDE. Report numbers: E2B_04921073, E2B_04852557, 000973761, E2B_04847601, E2B_04781885, 000970718, 000974497.Organization: Health Canada
September 2022
Req # A-2021-002135
Adverse Drug Reactions (ADRs) for METRONIDAZOLE, CLOPIDOGREL BISULFATE, FLUZONE QUADRIVALENT. Report numbers: E2B_04916460, E2B_04701007, E2B_04941688, 000973713.Organization: Health Canada
September 2022